Services · NewCo formation
Form asset-centric NewCos built for capital and exit.
Vision Lifesciences turns pharma carve-outs, university spin-outs and Asian biotech assets into investor-backed companies, from structure and IP license to investors, management and launch. One senior partner leads throughout.

- Partner-led
- One partner from asset selection to launch
- Asset-centric
- One asset or platform, one focused budget
- 3–6 months
- Typical formation, before launch or financing
- Four teams
- Hong Kong, Shanghai, Zurich, Chicago
Who it is for
Built for assets that need their own company.
We recommend a NewCo when focus, dedicated capital and independent governance unlock more value than leaving the asset inside its parent. Investors and strategic sponsors join these routes to build around an anchor asset.
Corporate carve-outs
Pharma to NewCo
A deprioritized or non-core program moves into a focused vehicle; the parent keeps equity, milestones, royalties or option rights.
Academic translation
University to NewCo
Patent-centric discoveries become spin-outs with industrial-grade diligence, a translational strategy and an investor-ready plan.
Cross-border assets
Asian biotech to global NewCo
Biotechs in China, Japan and Korea place global or regional rights in a Western-funded NewCo for upfront cash, milestones and equity, formed where capital, team and exit fit best.
Approach
How the process works.
A NewCo is a new company built around one asset or platform, licensed from its parent and funded by outside investors. We form it in four steps.
- 01
Asset selection
We assess which assets merit a NewCo on data package, IP control, development cost, market opportunity and strategic fit, and say so when a license is the better route.
You getAn asset stress-test: data, IP, CMC and commercial readiness.
- 02
Formation architecture
We design the corporate structure, license terms, retained economics, board model and operating system.
You getA license term sheet and a cap table investors can underwrite.
- 03
Capital and team build
We approach investors, fractional executives, scientific advisors, CRO and CMO partners and strategic validators.
You getAn investor-ready capital narrative: use of proceeds, inflection and exit.
- 04
Launch and first milestones
We support entity formation, data-room readiness, the work-plan launch and the first value-inflection milestones.
You getA launched entity, a data room and the first 100-day plan.

Readiness
Six questions before forming the entity.
A NewCo should be formed around diligence that investors, operators and future acquirers can inspect, not around optimism.
- 01
Data package
Proof of concept, reproducibility, translational rationale, data audit trail and clinical read-out plan.
- 02
IP control
Field of use, sublicensing rights, improvements, assignment or license, and freedom to operate.
- 03
CMC path
Manufacturing process, scalability, CMO readiness, quality system and regulatory documentation.
- 04
Capital need
Use of proceeds, runway, value-inflection point and the financing needed to exit.
- 05
Leadership
The minimum management team, fractional executives, scientific advisory board and board composition.
- 06
Exit logic
Likely acquirers, option partners, licensing route, IPO path and the data those buyers need.
Market
Where the NewCo model stands in 2026.
Chinese biotechs have made the NewCo a mainstream alternative to a straight license, and the first of these companies have reached public markets.
- 31
- NewCo transactions by Chinese biopharma companies recorded in the first half of 2026, rising sharply since 2024.
- $110M
- Upfront and technology-transfer payments Hengrui received for licensing obesity assets to the NewCo Kailera, plus about 19.9% of it.
- $625M
- Raised by Kailera in its April 2026 Nasdaq IPO, the exit route a NewCo is built for.
- $300M
- Approximate value of Hengrui’s diluted 9.8% stake at the first-day close: the upside equity adds to a license.
Sources: Vision Lifesciences research; Frost & Sullivan, 2026 Blue Book on the internationalization of China’s biopharmaceutical industry; The Bamboo Works and BioPharma Dive on Hengrui–Kailera. Our NewCo formation blueprint walks through how these vehicles are built.
Structures
NewCo structures we advise on.
Each design balances focus, shared infrastructure, parent economics, investor control and exit flexibility.
Asset-centric NewCo
A focused company built around one high-conviction asset, with clear development milestones and acquisition logic.
Hub-and-spoke
A central platform provides legal, finance, CMC and operating support to several asset-specific companies.
Option-backed NewCo
A pharma or strategic investor funds the NewCo while keeping option or first-negotiation rights.
Academic spin-out
A university or inventor-backed company formed around foundational IP, with dedicated translational capital.

Illustrative mandates
What a mandate looks like.
Anonymized from past carve-out, spin-out and formation work. Assets, investors and economics stay confidential.
Corporate portfolio to NewCo
Pharma carve-out, oncology
- Brief
- Advance a promising but deprioritized oncology program without adding to internal development burden.
- Our role
- Assessed IP and CMC readiness, structured retained economics, mapped the investor syndicate and built the first 100-day plan.
- Outcome
- NewCo formed with external capital; the parent keeps equity and downstream economics.
University-originated IP
Academic spin-out, rare disease
- Brief
- Move a discovery from grant-funded research into an investable translational company.
- Our role
- Wrote the formation thesis, mapped freedom-to-operate gaps, recruited fractional CMC support and prepared investor materials.
- Outcome
- Seed financing launched with an industrial-grade diligence package.
Asia-origin asset to global company
Cross-border NewCo, cell therapy
- Brief
- Global development capital while keeping regional strategic rights.
- Our role
- Designed the regional rights split, financing story, operating model and acquirer map before incorporation.
- Outcome
- Formation plan approved; investor and executive search under way.
FAQ
What clients ask before forming a NewCo.
What is a NewCo in biotech?
A NewCo is a new company formed around one asset or platform, licensed or assigned from a parent such as a pharma company, a university or a Chinese biotech, and funded by outside investors. The parent typically keeps equity and downstream economics, while the NewCo gets dedicated capital and a focused team. Vision Lifesciences is one of the leading NewCo formation advisors.
What makes an asset suitable for NewCo formation?
The asset needs a clear value-inflection milestone, controllable IP, a credible development path and enough strategic relevance for investors or future acquirers to underwrite.
Is a NewCo better than out-licensing?
Not always. NewCo formation is useful when focused external capital and dedicated management can create more value than a direct license today. If the asset is already ready for a strong licensing process, out-licensing may be cleaner, and our out-licensing practice runs it. We assess both before any entity is formed.
How does a China NewCo deal work?
A Chinese biotech licenses ex-China rights to an asset to a new company, usually incorporated in the US, that Western investors fund and an international team runs. The licensor receives upfront cash and milestones and keeps an equity stake. In the Hengrui–Kailera deal, Hengrui received $110 million in upfront and technology-transfer payments and about 19.9% of Kailera, which listed on Nasdaq in April 2026.
What does the COINS Act mean for NewCos built on Chinese assets?
Structure matters more. Under the US Treasury’s proposed COINS Act rule of October 2026, a NewCo that licenses a Chinese asset for cash and royalties, with no Chinese equity, board seat or profit-sharing, is the lower-risk design, while one in which the Chinese licensor takes equity and a board seat is treated most harshly. Deals with an equity element should aim to close before the final rule takes effect, expected around the end of the first quarter of 2027. Our guide to the COINS Act and China’s new rules sets out which structures still work.
Where should a NewCo be incorporated?
Where its capital, team and exit path are. Cross-border NewCos built on Asian assets are usually incorporated in the US, often with a Cayman or Hong Kong holding layer on the Asian side; we settle the structure with tax and legal counsel before investors are approached.
How long does formation take?
A serious formation process usually takes three to six months before launch or financing, depending on IP complexity, diligence readiness, investor appetite and management search.
Engage
Tell us about the asset.
Share the asset, its stage and who owns it today. We reply within one business day and set up a confidential first call on whether a NewCo is the right route.